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these functions: one resembling C-type lectins and the
other comprising immunoglobulin (Ig) domains (re-
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Two subfamilies of KIR are specific for determinants
The expression of KIR and CD94:NKG2 receptors was of HLA-C produced by alternative sequence motifs at
determined for more than 100 natural killer (NK) cell positions 77 and 80 of the HLA-C heavy chain (Colonna
clones obtained from two blood donors who differ in et al., 1993a, 1993b; Moretta et al.,1993). A thirdsubfam-
their HLA class I and KIR genes. More than 98% of the ily of KIR is specific for the Bw4 sequence motif found
clones were inhibited by individual autologous class I at residues 77±83 on one third of HLA-B heavy chain
allotypes, and every clone was inhibited by the combi- allotypes (Litwin et al., 1994; Gumperz et al., 1995). The
nation of autologous allotypes. The patterns of inhibi- inhibitory specificity of the fourth subfamily of KIR has
tion correlate with expression of inhibitory receptors been reported to include certain HLA-A allotypes (DoÈ hr-
of defined specificity. One donor possesses three ing et al., 1996; Pende et al., 1996). Whereas the individ-
class I ligands for KIR, and a majority of NK cells ual KIR specificities are confined to the allotypes of a
use KIR as their inhibitory receptor; the second donor single HLA class I locus, the lectin-like CD94:NKG2a
possesses only a single ligand for KIR, and a majority receptor has a broad specificity that includes a majority
of NK cells use the more broadly reactive CD94:NKG2a of HLA-A, -B, and -C allotypes and the nonclassic HLA-G
as their inhibitory receptor. Because of these differ- molecule (Phillips et al., 1996; PeÂ rez-Villar et al., 1997;
ences, the first donor has subpopulations of NK cells SoÈ derstroÈ m et al., 1997). Both the KIR family and the
that kill cells of the second donor, whereas the NK NKG2 family contain members for which HLA class I
cells of the second donor are universally tolerant of specificities have not been defined. About half of the
cells from the first donor. family members lack immune receptor tyrosine-based
inhibitory motifs (ITIM) and cannot deliver inhibitory sig-
nals (Moretta et al., 1995; Biassoni et al., 1996; Houchins
Introduction
et al., 1997; Olcese et al., 1997). The function of these
ªnoninhibitoryº receptors remains uncertain.
KaÈ rre and coworkers proposed the missing-self model
NK cells can be divided into subpopulations based
as a physiological context for their observation that cel-
on the class I receptors they express (Moretta et al.,
lular expression of major histocompatibility complex
1990; Ciccone et al.,1992; Karlhofer et al.,1992; Brennan
(MHC) class I molecules conferred resistance to lysis
et al., 1994, 1996; Mason et al., 1995). Therefore, like T
by natural killer (NK) cells (KaÈ rre et al., 1986; Ljunggren
cells, there is thepotential for an NK cell repertoire withinand KaÈ rre, 1990). The model predicts that circulating
an individual's immune system. Unlike T cells, individualNK cells survey the body for MHC class I expression
NK cells can express more than one receptor, and ex-and kill cells in which it is abnormally down-regulated.
pression of a receptor by an NK cell does not dependConsistent with the missing-self model has been the
upon expression of a corresponding MHC class I liganddiscovery of receptors on rodent and human NK cells
(Karlhofer et al., 1992; Lanier et al., 1995; Gumperz etthat bind to polymorphic determinants of MHC class I
al., 1996; Raulet et al., 1997). A corollary of the missing-molecules and signal inhibition of cytolysis (Karlhofer et
self model is that NK cells do not kill autologous cellsal., 1992; Moretta et al., 1993; Litwin et al., 1994; Moretta
expressing the normal set of MHC class I molecules.et al., 1994). Two kinds of cell-surface glycoprotein have
This predicts that every circulating NK cell in an individ-
ual should express at least one receptor that has speci-³To whom correspondence should be addressed (e-mail: peropa@
ficity for a self HLA class I ligand. We tested this predic-leland.stanford.edu)
tion by determining the NK cell receptor repertoires of§Present address: Immunology Graduate Group, Harvard Medical
School, Boston, Massachusetts 02115. two healthy individuals.
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Figure 1. Inhibition of NK Cell Clones from Donors PP and NV by Self Class I Allotypes
NK cell clones from PP (A and C) and NV (B and D) were used as effectors in cell-killing assays against the autologous B cell lines and the
221 transfectants bearing autologous class I allotypes.
(A and B) The percentage of NK clones inhibited (defined as .20% inhibition compared to lysis of untransfected 221 cells) was calculated
for each transfectant, and more than 100 clones (n 5 108 for PP and n 5 111 for NV) were analyzed for each donor.
(C and D) Fifty clones randomly selected from the clones generated in a single cloning experiment were analyzed for the extent of inhibition
mediated by the autologous HLA class I allotypes. The results for each NK cell clone/target cell pair are plotted as percentage inhibition
compared to lysis of the untransfected 221 cells.
Results cell lines were lysed by NK cell clones, demonstrating
theclass Idependence of the inhibition (data not shown).
The transfectants expressing single HLA class I allo-Human NK Cells All Can Be Inhibited by One or
More Autologous HLA-A, -B, or -C Allotypes types were lysed to varying degrees by the different NK
cell clones, but in a reproducible pattern. Almost allBoth of the donors studied are heterozygous for the
HLA-A, -B, and -C loci. Although one HLA class I haplo- (.98%) of the NK cell clones were inhibited by one or
more of the self HLA class I allotypes. The NK cell clonestype (A*0301, B*0702, and Cw*0702) is shared, the differ-
ences at the other haplotype are such that donor PP from PP were largely of two kinds: the majority of clones
were inhibited by the A*0101, A*0301, B*0702, andpossesses only one of the well-defined ligands for KIR,
the group 1 HLA-C ligand, whereas donor NV possesses Cw*0304 allotypes, and the minority of clones were in-
hibited by Cw*0304 and Cw*0702 (Figure 1A). The levelall three of them, the group 1 and 2 HLA-C ligands and
the Bw4 HLA-B ligand (Table 1). Transformed B cell of class I±mediated inhibition for NK cell clones in the
latter group was significantly stronger than for those inlines were established from each donor, and from these,
cDNA corresponding to the six HLA class I alleles were the former group (Figure 1C). The B*1501 allotype was
striking for its lack of inhibitory capacity.cloned, sequenced, and transfected into the class
I±deficient B cell line 721.221 (221). More than 100 NK By contrast to the differential inhibition seen for the
HLA class I allotypes of donor PP (Figure 1A), all sixcell clones were established from each donor and tested
for their capacity to lyse the autologous B cell line, the of NV's allotypes inhibited a substantial number of the
autologous NK cell clones, with the Cw*0202 allotype221 cell line, and the panel of 221 transfectants express-
ing individual autologous HLA class I alleles (Figure 1). inhibiting more than 70% of the clones (Figure 1B). For
donor NV, most of the NK cell clones divide into threeWhereas all NK cell clones from both donors lysed
the class I±deficient 221 cell line, none lysed the autolo- groups: those inhibited by A*0201, A*0301, B*0702,
B*2702, and Cw*0202; those inhibited strongly bygous B cell line. However, in the presence of a monomor-
phic anti-HLA class I monoclonal antibody (MAb), the B Cw*0702; and those inhibited strongly by Cw*0202 (Fig-
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ure 1D). These results demonstrate how every mature
human NK cell can be inhibited by one or more autolo-
gous HLA class I allotypes.
Individual Humans Express Different
Subsets of KIR Family Members
The functional analysis (Figure 1) shows that individual
NK cells from donors PP and NV are differentially inhib-
ited by self HLA class I allotypes. We therefore corre-
lated these differences with the expression of NK cell
receptors for HLA class I. Both the Ig-like KIR and the
lectin-like CD94:NKG2 receptors were analyzed. From
the published sequences for CD94 and NKG2 family
members, oligonucleotide primers were designed for
the amplification of cDNA,and these products were then
sequenced (Houchins et al., 1991; Chang et al., 1995).
Both donors were shown to express the CD94, NKG2a,
and NKG2c genes (Table 1).
Using oligonucleotide primers designed from the pub-
lished KIR sequences, we cloned and sequenced KIR
cDNA from resting peripheral blood lymphocytes; acti-
vated, polyclonal NK cells; and selected NK cell clones
from the two donors. Both individuals express 11 differ-
ent KIR: 3 are held in common and 8 are different (Table
1). The inhibitory KIR can be divided into four groups Figure 2. Donors PP and NV Possess Distinct Sets of KIR Genes
(KIR2DL1, KIR2DL2/3, KIR3DL1, and KIR3DL2) associ- PCR-SSP typing for the NK cell receptor subfamilies indicated was
performed on cDNA and genomic DNA samples isolated from PBMCated with different HLA class I specificities, and both
or EBV-transformed BLCLs, respectively. Different pairs of oligonu-donors express representatives of all four groups, with
cleotide primers were used for the amplification of class I receptorPP expressing two representatives of each group and
sequences from the two DNA sources. The PCR products were
NV only one. By contrast, NV expresses five of the nonin- resolved by agarose gel electrophoresis and analyzed under ultravi-
hibitory KIR, whereas PP expresses just one. In addition, olet light for ethidium bromide staining. For amplifications with
both individuals express two versions of the structurally cDNA, primers specific for b-actin were included as a positive con-
trol, and the position of this product is indicated.divergent KIR family member, KIR2DL4 (103AS), (Selva-
kumar et al., 1996).
To characterize the class I receptors of the NK cell
clones used in the functional analysis (Figure 1), we independently by antibody binding and flow cytometry
typed for KIR, CD94, and NKG2 cDNA using a method on polyclonal, peripheral blood NK cells (Figures 3B and
of PCR-SSP (polymerase chain reaction±sequence spe- 3D). This concordance indicates that our method of NK
cific priming) typing developed by Uhrberg et al. (1997 cell cloning introduces little bias toward particular sub-
[this issue of Immunity]). Systematic analysis of the NV populations of NK cells, giving confidence that assess-
and PP panels of NK cell clones confirmed that their ment of the patterns of class I receptor expression ob-
class I receptors expressed are included in those ob- tained from NK cell clones reflects those of the NK cell
tained from the sequence analysis. Moreover, except populations in vivo. The exception to this generalization
for NKG2c, which was not detected in PP'sNK clones, all was that the NK cell clones obtained from NV were
of the receptors for which sequences had been obtained enriched for expression of CD94:NKG2a when com-
were represented in the panel of NK cell clones. Anti- pared to his peripheral blood NK cells (Figure 3D).
body binding and flow cytometric analysis of NK cell The two donors differ not only in their complement of
clones from both donors revealed that whenever a tran- KIR genes, but also in the extent to which they use them
script was detected it gave rise to receptor expression (Figure 3). The only receptor expressed by every NK cell
at the cell surface (data not shown and Uhrberg et al., clone is KIR2DL4 (103AS), a structurally divergent family
1997). The differential patterns of KIR gene expression in member of unknown function. The majority of donor
the peripheral blood NK cells from NV and PP correlated PP's NK cells express the inhibitory receptors KIR3DL2
precisely with differences observed at the genomic level or CD94:NKG2a or the noninhibitory receptor KIR2DS4,
(Figure 2). whereas no single inhibitory or noninhibitory receptor
is expressed by more than half of the NK cells from NV
(Figures 3A and 3C). Similar numbers of NK cells fromHuman NK Cells Express 2±9 KIR and CD94:NKG2
both donors express inhibitory receptors from theReceptors per Cell
KIR2DL1, KIR2DL2/3, and KIR3DL2 subfamilies evenThe results from PCR-SSP typing of the panels of NK
though donor PP has no class I ligand (group 2 HLA-C)cell clones were compiled to assess the relative number
for KIR2DL1. For KIR3DL1 expression, the two donorsof NK cells expressing each receptor (Figures 3A and
3C). The values obtained are similar to those determined differ substantially: in PP approximately 50% and in NV
Immunity
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Table 1. HLA Class I Ligands and Receptors of Donors PP and NV
HLA Class I Ligands
PP NV
Allotypesa KIR Epitopesb Allotypesa KIR Epitopesb
A*0101 Unknown A*0201 Unknown
A*0301 Unknown A*0301 Unknown
B*0702 Unknown B*0702 Unknown
B*1501 Unknown B*2702 Bw4 HLA-B
Cw*0304 Group 1 HLA-C Cw*0202 Group 2 HLA-C
Cw*0702 Group 1 HLA-C Cw*0702 Group 1 HLA-C
HLA Class I Receptors
PP NV
Receptor Subfamilyc Receptorsd Receptor Subfamilyc Receptorsd Specificity
Inhibitory KIR Inhibitory KIR
KIR2DL1 NKAT1 KIR2DL1 KIR2DL1v Group 2 HLA-C
p58cl42
KIR2DL3 NKAT2A KIR2DL2 p58cl43 Group 1 HLA-C
KIR2DL3v
KIR3DL1 NKAT3 KIR3DL1 KIR3DL1v Bw4 HLA-B
NKB1
KIR3DL2 NKAT4 KIR3DL2 AMC5/cl5 HLA-A?
AMC5/cl5
KIR2DL4 KIR2DL4v1 KIR2DL4 KIR2DL4v1 Unknown
KIR2DL4v2 KIR2DL4v3
Noninhibitory KIR Non-inhibitory KIR
KIR2DS1 KIR2DS1v Group 2 HLA-C
KIR2DS2 NKAT5 Group 1 HLA-C
KIR2DS3 KIR2DS3v Unknown
KIR2DS4 p58cl39 KIR2DS4 p58cl39 Unknown
KIR3DS1 KIR3DS1v Unknown
Inhibitory Lectins Inhibitory Lectins
CD94:NKG2a CD94:NKG2a CD94:NKG2a CD94:NKG2a HLA-A, -B, and -C
Noninhibitory Lectins Noninhibitory Lectins
CD94:NKG2c CD94:NKG2C CD94:NKG2c CD94:NKG2C Unknown
a The HLA class I alleles were identified by nucleotide sequencing.
b The predicted KIR epitopes for each class I allele were determined from the deduced amino acid sequences of the HLA class I heavy chain
allotypes. The group 1 and 2 HLA-C epitopes are distinguished by the diallelic positions Ser 77, Asn 80 (group 1) and Asn 77, Lys 80 (group
2) (Colonna et al., 1993b).
c The different class I receptors (KIR and CD94/NKG2) were grouped into subfamilies as described (Uhrberg et al., 1997). The system of
nomenclature used for KIR subfamilies was suggested by E. Long (National Institutes of Health, Bethesda, MD), L. Lanier (DNAX Institute,
Palo Alto, CA), and M. Colonna (Basel Institute, Basel, Switzerland). This system takes into account the different number of extracellular
immunoglobulin domains, the lengths of the cytoplasmic tails, and the nucleotide sequence relationships of the different KIR family members.
It also correlates with the class I specificity and antibody reactivity of the different receptors. All known KIR can be divided into two groups
based on the presence of two or three extracellular immunoglobulin domains; these are designated KIR2D and KIR3D, respectively. The
receptors can also be divided based on the length of their cytoplasmic tails. Receptors having long tails are designated L, and those having
short tails are designated S. Inhibitory receptors have long cytoplasmic tails possessing two ITIM motifs, whereas noninhibitory receptors
have short tails and lack ITIMs. Similarly, the heterodimeric CD94:NKG2 receptors are divided based on the presence (inhibitory lectins) or
absence (noninhibitory lectins) of ITIMs in the cytoplasmic tails of their NKG2 chains (Houchins et al., 1997).
d The KIR sequences characterized for each donor are listed. Variant sequences not identified previously are designated with a v. Eight variants
differ from known KIR subfamily members by one or two nucleotide substitutions. The KIR2DL1 variant from donor NV differed from other
KIR2DL1 subfamily members by nine or ten nucleotide changes, seven of which are shared by KIR2DL1v and the KIR2DS1 sequences:
EB6Act1 and EB6Act2 (Biassoni et al., 1996). The KIR2DS1v, KIR2DS3v, KIR3DS1v, and KIR2DL4v sequences are related to EB6Act1, NKAT7,
NKAT10, and 103AS sequences, respectively.
approximately 5% of NK cells express this KIR subfam- resembles a normal distribution (Figure 4). NK cells from
PP tend to express more receptors than those from NV,ily, even though NV possesses a class I ligand (Bw41
HLA-B) for this receptor but PP does not. as seen from the modal number of receptors expressed
per cell, 5 for PP and 4 for NV, as well as the meanIndividual NK cell clones from both donors were found
to express between 2 and 9 different molecules of the numbers of receptors expressed per cell, 4.5 for PP and
4.2 for NV. Limiting the analysis to receptors that haveKIR and CD94:NKG2 families combined. The frequen-
cies of cells expressing different numbers of receptors inhibitory (ITIM) motifs in theircytoplasmic tails or recep-
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Figure 3. Frequencies of Expression of the Different Class I Receptor Subfamilies
The numbers of NK cells from donor PP (A and B) and donor NV (C and D) expressing class I receptors were determined by two methods.
(A and C) PCR-SSP typing of NK cell clones (n 5 108 for PP and n 5 111 for NV) was used to determine the clones expressing transcripts
for the indicated inhibitory (solid bars) and noninhibitory (striped bars) receptors.
(B and D) The percentages determined by PCR typing (hatched bars) are compared to the results from three-color flow cytometric analyses
(open bars) obtained by staining donor-derived PBMC with antibodies specific for different class I receptor subfamilies.
For flow cytometric analyses the percentage of cells expressing each receptor was calculated on the CD32CD561 NK cell subset. Antibodies
used were Leu4 (anti-CD3), Leu19 (anti-CD56), EB6 (anti-KIR2DL1 and anti-KIR2DS1), DX27 (anti-KIR2DL2/3 and anti-KIR2DS2), DX9 (anti-
KIR3DL1), DX31 (anti-KIR3DL2), and a rabbit polyclonal antiserum specific for CD94:NKG2a. FACS, fluorescence-activated cell sorting.
tors that do not reveals a greater difference between is some limitation on the simultaneous expression of
the inhibitory KIR and CD94:NKG2a receptors.the two donors. NK cells from PP have a range of 2±6
inhibitory receptors per cell and a mode of 4, whereas
those from NV have a range of 2±5 and a mode of 3. The Inhibitory Receptor Repertoire of Donor
PP Is Dominated by One Lectin-likeBy contrast, NV's NK cells express more noninhibitory
receptors (0±5 per cell) than do those from PP (0±1 per Receptor and One Ig-like Receptor
For each NK cell clone the patterns of receptor expres-cell).
All of PP's and NV's NK cell clones express more sion determined by PCR-SSP and self HLA class I±medi-
ated inhibition of cytolysis were compared. Expressionthan one class I receptor. We calculated the observed
frequencies for combinations of receptors and com- of receptors of known HLA class I specificity can ac-
count for the functional inhibition of more than 95%pared them to those expected from the products of their
individual frequencies. In almost all cases the observed of the PP NK cell clones (Figure 1). That the assigned
receptors were responsible for the inhibition was con-and expected frequencies were similar (Table 2). The
significant exception was that the frequencies of NK firmed by showing that receptor-specific antibodies in-
terfered with inhibition (data not shown). For donor PP,cells expressing CD94:NKG2a in association with any
inhibitory KIR were lower than expected from random the HLA class I±mediated inhibition of NK cell clones
appears mainly to be accounted for by two receptors:association. This trend, observed for both donors, was
most striking for NK cell clones bearing CD94:NKG2a KIR2DL3 and CD94:NKG2a. KIR2DL3 is expressed by
36% of PP's NK cells, which constitute the subsetand no inhibitory KIR (excluding KIR2DL4/103AS), whose
observed frequency in both donors was .3 times higher strongly inhibited by the autologous HLA-C allotypes
(Cw*0304 and Cw*0702). CD94:NKG2a is expressed bythan would have been predicted from random associa-
tion (data not shown). Although the expression of indi- 72% of PP's NK cells, which constitute the subset inhib-
ited by A*0101, A*0301, B*0702, and Cw*0304 (Figurevidual KIR family members is largely stochastic, there
Immunity
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Figure 5. Specificity of the CD94:NKG2a Receptor for Four of the
HLA Class I Allotypes of Donor PP
(A) Fifteen NK cell clones selected for expression of CD94:NKG2a
and lack of expression of inhibitory KIR (KIR2DL1, KIR2DL3,
KIR3DL1, and KIR3DL2) were tested for their inhibition by autolo-
gous HLA class I allotypes. The inhibitory pattern of these
CD94:NKG2a-dependent, KIR-independent clones is compared
with that of all (n 5 108) NK cell clones obtained from donor PP (B).
for the inhibition by Cw*0304 not mediated by KIR2DL3.
Other investigators have proposed that KIR3DL2 (p140;
NKAT4) has inhibitory specificity for A*0301 (DoÈ hring et
al., 1996; Pende et al., 1996). Although this receptor is
Figure 4. NK Cell Clones from PP and NV Express 2±9 KIR and
expressed by 66% of PP's NK cells, we found no correla-CD94:NKG2 Family Members
tion between expression of KIR3DL2 and the suscepti-The results from the PCR typing assays were compiled and used
bility of an NK cell to inhibition by the self allotypeto determine the percentage of NK cell clones of donors PP (striped
A*0301. The same result was obtained from analysis ofbars) and NV (solid bars) expressing different numbers of class I
receptors. The receptors listed in Table 1 are included in the analysis the NK cells from NV, who expresses HLA-A*0301 and
and are divided into three groups: (A) all receptors; (B) inhibitory hasKIR3DL2 on 50% of his NK cells. Furthermore, inhibi-
receptors; and (C) noninhibitory receptors. All of the NK cell clones tion of NK cell cytotoxicity by the A*0301-expressing
from both donors expressed the inhibitory receptor KIR2DL4
transfectant was not perturbed by the addition of(103AS).
KIR3DL2-specific antibody to cell-killing assays (data
not shown). For these two donors, inhibition by A*0301
1). The inability of B*1501 to inhibit efficiently any NK appears to be mediated solely through the lectin-like
cell clone suggests that it is not a ligand for the inhibitory receptor, CD94:NKG2a.
receptors (KIR or CD94:NKG2a) found in this individual's Further demonstration that inhibition of PP's NK cells
repertoire. by self HLA class I is mediated largely through engage-
To test the hypothesis that CD94:NKG2a is responsi- ment of the KIR2DL3 and CD94:NKG2a receptors came
ble for the pattern of inhibition produced by A*0101, from examining the effects of different anti-receptor an-
A*0301, B*0702, and Cw*0304 (Figure 1), we analyzed tibodies on the inhibition (Figure 6). The only antibodies
the inhibition by self HLA class I allotypes of NK cell that enabled clones of PP's NK cells to lyse the autolo-
clones from PP that are devoid of inhibitory KIR (exclud- gous B cell line were ones with specificity for KIR2DL3
ing KIR2DL4). All these clones have CD94:NKG2a as or CD94:NKG2a (Figures 6A±6D). NK cell clones ex-
their only inhibitory receptor, and almost all were inhib- pressing KIR2DL3 in the absence of CD94:NKG2a lysed
ited by the self allotypes A*0101, A*0301, B*0702, and autologous B cells in the presence of anti-KIR2DL3,
Cw*0304, but not by B*1501 and Cw*0702 (Figure 5). while, conversely, NK cell clones expressing CD94:NKG2a
Thus, the CD94:NKG2a receptor accounts for all of the but not KIR2DL3 lysed autologous B cells in the pres-
ence of anti-CD94:NKG2a. Clones expressing bothinhibition produced by A*0101, A*0301, and B*0702 and
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Table 2. Comparison of Observed and Expected Frequencies of NK Cell Receptor Pairs
PP
KIR2DL1 KIR2DL3 KIR3DL1 KIR3DL2 KIR2DS4
Receptors (0.38) (0.36) (0.48) (0.66) (0.85)
KIR2DL1 Obs. Ð
(0.38) Exp. Ð
KIR2DL3 Obs. 0.17 Ð
(0.36) Exp. 0.14 Ð
KIR3DL1 Obs. 0.20 0.19 Ð
(0.48) Exp. 0.18 0.17 Ð
KIR3DL2 Obs. 0.26 0.25 0.28 Ð
(0.66) Exp. 0.25 0.24 0.32 Ð
KIR2DS4 Obs. 0.32 0.31 0.43 0.55 Ð
(0.85) Exp. 0.32 0.31 0.41 0.56 Ð
CD94:NKG2a Obs. 0.21 0.19 0.28 0.42 0.64
(0.72) Exp. 0.27 0.26 0.35 0.48 0.61
NV
KIR2DL1 KIR2DL2 KIR3DL2 KIR2DS2 KIR2DS3 KIR2DS4 KIR3DS1 CD94:NKG2a
Receptors (0.28) (0.51) (0.50) (0.50) (0.12) (0.44) (0.25) (0.50)
KIR2DL1 Obs. Ð
(0.28) Exp. Ð
KIR2DL2 Obs 0.10 Ð
(0.51) Exp. 0.14 Ð
KIR3DL2 Obs. 0.12 0.29 Ð
(0.50) Exp. 0.14 0.25 Ð
KIR2DS2 Obs. 0.20 0.25 0.29 Ð
(0.50) Exp. 0.14 0.25 0.25 Ð
KIR2DS3 Obs. 0.05 0.07 0.07 0.08 Ð
(0.12) Exp. 0.03 0.06 0.06 0.06 Ð
KIR2DS4 Obs 0.16 0.25 0.27 0.29 0.07 Ð
(0.44) Exp. 0.12 0.22 0.22 0.22 0.05 Ð
KIR3DS1 Obs 0.11 0.16 0.14 0.16 0.06 0.14 Ð
(0.25) Exp. 0.07 0.13 0.13 0.13 0.03 0.11 Ð
CD94:NKG2a Obs 0.07 0.16 0.19 0.20 0.05 0.23 0.13 Ð
(0.50) Exp. 0.14 0.25 0.25 0.25 0.06 0.22 0.13 Ð
CD94:NKG2c Obs. 0.05 0.14 0.14 0.13 0.05 0.12 0.05 0.11
(0.21) Exp. 0.06 0.11 0.10 0.10 0.03 0.09 0.05 0.10
The NK cell receptors are listed with their individual frequencies in parentheses. Analysis was not performed on CD94:NKG2c for PP or on
KIR3DL1 or KIR2DS1 for NV because these receptors are expressed at too low a frequency. The observed (obs.) frequencies for each receptor
pair were calculated from PCR typing of more than 100 NK clones from each donor (n 5 108 for PP; n 5 111 for NV). The expected (exp.)
frequencies for random expression of receptor pairs are the products of each receptor's individual frequency. The underlined values differ
significantly (P , 0.01) from that expected by random association. Statistical significance was determined using a 2 3 2 analysis in combination
with a G test of independence.
KIR2DL3 and CD94:NKG2a lysed autologous B cells in Some 5% of the NK cell clones obtained from PP
express neither KIR2DL3 nor CD94:NKG2a. For thesethe presence of the combination of anti-KIR2DL3 and
anti-CD94:NKG2a but not in the presence of either anti- clones, the inhibition by transfectants expressing indi-
vidual self HLA class I alleles was difficult to discern,body alone (Figure 6D). Antibodies specific for other
inhibitory receptors had no effect on the resistance to since the effects were weak and variable. However, 221
cells were consistently killed by these cells, whereaslysis of the autologous B cell targets, even though many
of the NK cell clones expressed the receptors. the autologous B cell line was resistant to their lysis, in
a manner that could be overcome by the inclusion ofSimilar effects were seen in cytolytic assays using
polyclonal NK cells from PP as the effector cells and anti-HLA class I MAb (data not shown). Inhibition of
clones such as these may require the combined effectsthe autologous B cell line as the target, a situation in
which all of the inhibitory interactions between the do- of two or more self HLA class I allotypes.
nor's NK cell receptors and class I ligands are assessed
simultaneously. Addition of antibodies specific for either The Inhibitory Receptor Repertoire of Donor NV
KIR2DL3 or CD94:NKG2a produced substantial lysis, Is Dominated by One Lectin-like Receptor
and addition of the two antibodies together gave an and Two Ig-like Receptors
The patterns of HLA class I±mediated inhibition of NV'seffect equivalent to that obtained with a monomorphic
anti-HLA class I antibody (Figure 6E). The presence of NK cell clones (Figure 1) correlated precisely with the
expression of specific receptors, and their involvementother antibodies specific for KIR2DL1, KIR3DL1, and
KIR3DL2 did not change appreciably the sensitivity of in the inhibition was demonstrated directly in antibody-
blocking experiments. All three well-established KIR li-the autologous B cell targets to lysis by donor PP's NK
cells. gands are represented in the self HLA class I allotypes
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Figure 6. Antibodies Specific for CD94, KIR2DL3, and HLA Class I Permit Lysis of Autologous Cells by Donor PP±Derived NK Cells
NK clones (A±D) or a polyclonal NK cell population (E) from donor PP were used as effectors in cell-killing assays against autologous BLCL
targets. Assays were performed in the presence (25 mg/ml) or absence of the indicated antibodies and the percentage specific lysis calculated.
Antibodies used were Leu19 (anti-CD56), DX17 (anti-class I), DX22 (anti-CD94), EB6 (anti-KIR2DL1 and anti-KIR2DS1), DX27 (anti-KIR2DL2/3
and anti-KIR2DS2), DX9 (anti-KIR3DL1), and DX31 (anti-KIR3DL2).
(A±D) For the experiments with clones, addition of MAbs Leu19, EB6, and DX9 did not affect NK cell cytolysis of autologous cells (data not
shown). The different combinations of inhibitory receptors expressed by the NK cell clones are listed below each clone designation.
(E) The polyclonal NK cells exhibited the same pattern of receptor expression seen for peripheral blood NK cells (data not shown).
of donor NV, who also expresses inhibitory KIR specific the autologous targets (Figures 7A±7D). The contribu-
tions of the different inhibitory receptors to NV's NKfor each of the ligands. Of these, the KIR3DL1 receptor,
which recognizes the autologous B*2702 allotype, is cell repertoire is reflected in the relative effects that
antibodies specific for the different receptors have onexpressed on very few of NV's NK cells (Figure 3). Each
of the receptors for the two different inhibitory epitopes the lysis of the NV B cell line by a polyclonal population
of NK cells. Whereas there is no lysis in the absenceof HLA-C is expressed on 30%±50% of the NK cells
and is responsible for the strong inhibition by HLA-C of antibody, the addition of antibodies specific for
KIR2DL1, KIR2DL2, and CD94:NKG2a all resulted insub-allotypes observed in Figure 1: KIR2DL1 has specificity
for Cw*0202 and KIR2DL2 has specificity for Cw*0702. stantial cytolysis (Figure 7E).
Although NV's NK cells express more noninhibitoryBy contrast, the inhibition by Cw*0202 not mediated
by KIR2DL1, the inhibition by B*2702 not mediated by KIR and NKG2 family members than PP's NK cells, the
presence of these receptors did not affect the functionsKIR3DL1, and all inhibition by A*0201, A*0301, and
B*0702 result from interaction with the lectin-like recep- of the inhibitory receptors when presented with a com-
patible HLA class I allotype. Even when a single inhibi-tor CD94:NKG2a. Only one NK cell clone obtained from
NV does not express a receptor of well-established HLA tory receptor was expressed in combination with five
noninhibitory receptors, as occurred for two of NV'sclass I specificity. Although expressing KIR3DL2, this
clone was inhibited poorly by all of the self HLA class I NK cell clones, inhibition predominated. NV expresses
inhibitory and noninhibitory receptors, both of whichallotypes when tested individually but was inhibited by
their combination as expressed on the autologous B can interact with the same HLA class I allotypes. For
example, KIR2DS2 (noninhibitory) and KIR2DL2 (inhibi-cell line (data not shown).
Antibodies specific for the different receptors were tory) are predicted to engage the self allotype Cw*0702
(Table 1). Of the more than 100 NK cell clones studied,tested for their capacity to disrupt the inhibitory interac-
tions between NV's NK cells and the autologous B cell 38 expressed such combinations of receptors, and in
every instance target-cell expression of their sharedline. Cell-killing assays with NV's NK cell clones demon-
strated that antibody blocking of the predicted inhibitory class I ligand by a 221 transfectant led to inhibition (data
not shown). These observations suggest that any signalreceptor±class I ligand interactions resulted in lysis of
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Figure 7. Antibodies Specific for CD94, KIR2DL1, KIR2DL2, KIR3DL1, and HLA Class I Permit Lysis of Autologous Targets by NK Cells from
Donor NV
Donor NV±derived NK clones (A±D) or a polyclonal NK cell population (E) were used as effectors in cell-killing assays against autologous
BLCL targets. Assays were performed in the presence (25 mg/ml) or absence of the antibodies indicated and the percentage specific lysis
determined. Antibodies used were the same as those in Figure 6. The different combinations of inhibitory receptors expressed by the NK cell
clones (A±D) are listed below each clone designation.
(A±D) For the experiments with clones, the antibodies not shown had no effect.
(E) The polyclonal NK cells exhibited the same pattern of receptor expression seen for peripheral blood NK cells (data not shown).
generated through engagement of the noninhibitory re- has ligands for both of these receptors there is no NK
cell alloreactivity of PP for NV. By contrast, NV has aceptors is subordinate to those transduced by the inhibi-
tory receptors, a thesis compatible with our failure to subset of NK cells that use the KIR2DL1 receptor as
their only inhibitory receptor for HLA class I, and amongfind any NK cell clone that lysed the autologous B cell
line. the HLA class I allotypes of PP there is no ligand for
this receptor. All of the NK cell clones from NV that kill
the PP B cell line express KIR2DL1 and do not expressHuman NK Cell Alloreactivity Is Determined
by the Combination of HLA Class I CD94:NKG2a or KIR2DL2, receptors that are inhibitable
by the HLA class I allotypes of PP. These observationsReceptors and Ligands
Since no NK cell from either donor lyses the autologous show that histocompatibility for NK cell alloreactions in
transplantation need not be dependent on HLA identity.B cell line and every NK cell is inhibitable by autologous
HLA class I, it seems likely that self HLA class I imposes
some selection on the receptors expressed by NK cells. Discussion
At a minimum, the requirement would be that every NK
cell expresses one inhibitory receptor that can be en- We can now describe in some detail the NK cell receptor
repertoire of two healthy persons who differ both in theirgaged by self class I. In that case NK cells from one
person need not be inhibitable by the HLA class I allo- HLA class I type and in their KIR type. For both donors
the expectations of the missing-self model were met:types of a secondperson (Morettaet al. 1990). To assess
this proposition for donors PP and NV, we examined first, every NK cell was inhibited by the combination of
self HLA class I allotypes and almost all were inhibited bythe extent to which NK cell clones from one donor could
be inhibited by the HLA class I allotypes of the other individual allotypes; second, the patterns of HLA class I
inhibition were highly correlated with the expression ofdonor (Figure 8). Some 15% of the NK cell clones from
NV lysed the B cell line from PP, whereas none of the functionally well-characterized receptors of particular
HLA class I specificity.NK cell clones from donor PP lysed the B cell line from
donor NV. In purely molecular terms, the human NK cell receptor
repertoire is highly diverse. For example, from more thanThe nature of this one-way alloreaction can be readily
interpreted in terms of the repertoire of class I receptors 100 NK cell clones established from each donor we
identified 33 distinct receptor (KIR and CD94:NKG2)expressed by the two donors. The CD94:NKG2a and
KIR2DL3 receptors are the dominant inhibitory recep- phenotypes for PP and 64 for NV. This diversity can be
attributed largely to the KIR family of class I receptorstors in the repertoire of PP, and since the NV B cell line
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Figure 8. A Subset of NK Cell Clones from
Donor NV Lyse PP BLCL
NK cell clones were tested for cytolysis of
autologous (NV, solid bars) or allogeneic (PP,
open bars) BLCL. Results are presented as
percentage specific lysis. Clones that failed
to lyse the PP BLCL express CD94:NKG2a
and/or KIR2DL2, whereas clones that lyse the
allogeneic target cells express neither recep-
tor. Data from ten representative NV clones
are shown. None of PP's NK cell clones lyses
either NV or PP BLCL (data not shown).
and involves contributions from the following effects: highly constrained, beyond the requirement for each cell
to express a receptor having specificity for a self HLA(1) individuals express the products of six or more differ-
ent KIR genes; (2) the KIR genes are polymorphic; (3) class I allotype. All of the genes possessed by an individ-
ual are expressed by some NK cells, and there is noNK cells can express 2±9 different receptors in different
combinations; and (4) persons express different combi- apparent limitation on the expression of several recep-
tors by a single cell or the expression of receptors fornations of HLA class I ligands, which during develop-
ment select compatible NK cells from the primary reper- which the self HLA class I type does not provide a ligand.
The frequency with which cells express a combinationtoire and ensure that NK cells without a receptor for self
HLA class I do not appear in the peripheral circulation of KIR is the product of the individual frequencies, as has
been observed similarly for the Ly49 class I receptors of(Uhrberg et al., 1997, and the present study).
In contrast to the complexity observed at the molecu- mouse NK cells, leading to proposal of the ªproduct
ruleº (Raulet et al., 1997). By contrast, the frequencieslar level, the ªfunctionalº repertoire of NK cell receptors
appears simple when considered in the context of inhibi- with which CD94:NKG2a is coexpressed with inhibitory
KIR on an NK cell's surface are lower than expectedtion by self HLA class I molecules. In PP's repertoire,
52.6% of the cells are regulated by CD94:NKG2a, 16.7% from the product rule. These observations provide evi-
dence for some coordination in expression of the twoare regulated by KIR2DL3, and 19.4% are regulated by
the combination of CD94:NKG2a and KIR2DL3. In NV's types of receptor. A hierarchy of receptor expression
might also exist between the KIR specific for HLA-B andrepertoire, 27.6% of the NK cells are regulated by
CD94:NKG2a, 14.2% by KIR2DL1, 24.2% by KIR2DL2, HLA-C, which would explain the observation that very
few of NV's NK cells use the KIR3DL1 receptor, although32.8% by any combination of two receptors, and 0.9%
by all three. the self HLA-B*2702 allotype is a good ligand for this
receptor.Within the two repertoires we studied, inhibition of
every NK cell appears to be signaled either through This investigation focused on defining the repertoire
of inhibitory receptors for self class I within individuala lectin-like receptor or through a KIR, and from the
perspective of the individual NK cell the two structurally humans. The results show that it can be defined largely
within the context of the receptors having well-defineddistinct types of receptors are seen to have equivalent
and independent functions. In both repertoires the lec- HLA class I specificity. Within the KIR family are addi-
tional molecules of unknown HLA class I specificity,tin-like and the Ig-like receptors divide the responsibility
for regulating NK cells, and in the context of an NK cell including ones that are noninhibitory receptors with and
without known class I ligands. In this analysis any func-population the two types of receptor are seen to be
complementary. Illustration of this complementarity is tional role of the noninhibitory receptors in binding self
HLA class I was found to be subservient to that of thethat NK cell clones (z20% in each donor) that lack all
four of the major inhibitory KIR (excluding KIR2DL4/ inhibitory receptors. However, the noninhibitory recep-
tors are expressed to a degree comparable to that of103AS) always express the CD94:NKG2a receptor. The
greater use of KIR by NV correlates with NV'spossessing the inhibitory receptors, with more than 80% of the NK
cells in both donors expressing one or more noninhibi-three different ligands for KIR and PP's having only one.
That a larger proportion of PP's NK cells express tory receptors.
Mice seem exclusively to use lectin-like molecules asCD94:NKG2a, for which almost all HLA-A, -B, and -C
allotypes are ligands, correlates with PP's having two the H-2 class I inhibitory receptors of their NK cells,
contrasting with the use of Ig-like and lectin-like recep-fewer ligands for KIR than NV. This difference suggests
that the extent to which CD94:NKG2a is used in an tors by humans (Gumperz and Parham, 1995; Valiante
et al., 1997). Despite this structural dichotomy, humansindividual's NK cell repertoire may be regulated by the
number of KIR that can be used as inhibitory receptors and mice do show similarities. In PP and NV, the relative
use of the lectin-like and the Ig-like receptors varies,for the set of self HLA class I allotypes.
The expression of the CD94:NKG2 and KIR families and so the difference between humans and mice might
better be thought of as a difference of quantity ratherof molecules on human NK cells does not seem to be
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NK cell receptor cDNAs were characterized by a similar strategy.than of quality. Furthermore, expression of the murine
Oligonucleotide primers based on conserved sequences of the KIRLy49 and human KIR family members appears to contain
family members were used to amplify by PCR cDNA from peripherala strong stochastic element, and the product rule gov-
blood mononuclear cells (PBMC), polyclonal cultured NK cells, and
erns the expression of most receptor combinations NK cellclones. Four different 59 primers (2IGF:59-GGGCGTCGACCC
(Raulet et al. 1997, and the present study). Recently, ATGGCGTGTGTTGGGTTCT239; 3IG59: 59-GGGCGTCGACCACTCA
TGGGTGGTCAGGAC239; NKAT1±59UT: 59-GCGCGTCGACTGCCTHeld and Raulet (1997) reported that the frequency of
GTCTGCTCC239; and cl11±59UT: 59- GGGCGTCGACGGCGCAGCCNK cells expressing an endogenous Ly49 receptor was
GCCTGTCG239) were paired with one 39 primer (NKR: 59-CGCCAAGreduced in mice transgenic for a different Ly49 receptor
CTTGTTTGAGACAGGGCTGTTG239). KIR2DL4 (103AS) sequenceshavingoverlapping H-2 specificity. This finding suggests
were amplified with an additional primer set (103AS59: 59-GCGCGTC
that selection by self class I can limit the number of GACTGCACCATGTCCATGTCA-39; and 2DL439UT-1: 59- CGCCGAA
inhibitory receptors per NK cell, and it is consistent with TTCGTGAGGAAGAGTGATGCT-39). Underlined sequences repre-
sent SalI, HindIII, and EcoRI restriction sites introduced into theour results showing that the NK cells from NV (three KIR
primers to allow cloning of the amplification products. 59 primersligands) express fewer inhibitory receptors per cell than
match 59 untranslated (UT) or signal peptide sequences of KIR, andthose of PP (one KIR ligand). These parallels suggest
the 39 primers match conserved sequences in the KIR 39UT. Thethat common principles govern the development of mu-
resulting products were subcloned into pBLUESCRIPT SK1 and
rine and human NK cell repertoires, despite the use of partially sequenced using a standard T7 or T3 primer and dye termi-
different receptors by the two species. nator automated sequencing (Applied Biosystems, Foster City, CA).
Three or four clones for each KIR family member identified wereThe one-way pattern of NK cell alloreactivity between
fully sequenced on both strands and a consensus sequence wasdonors PP and NV can be explained readily by differ-
determined. The GenBank accession numbers for the KIR variantsences inNK cell receptor repertoire and HLA class I type.
first identified here are KIR2DL1v (AF022045), KIR2DL3v (AF022048),Because NV and PP are heterozygous and homozygous,
KIR3DL1v (AF022049), KIR2DS1v (AF022046), KIR2DS3v (AF022047),
respectively, for KIR ligands, the NK cells of NV include KIR3DS1v (AF022044), KIR2DL4v1 (AF034771), KIR2DL4v2
some that cannot be inhibited by PP's HLA class I type, (AF034772), and KIR2DL4v3 (AF034773).
whereas all of PP's NK cells are inhibited by NV's HLA
PCR-SSP Typing for NK Cell Receptorsclass I type. Such alloreactivityof a heterozygote toward
The RT-PCR±based typing assay for KIR and CD94:NKG2 subfami-a homozygote is directly analogous to the NK cell±
lies is described in detail by Uhrberg et al. (1997).mediated rejection of parental bone marrow transplants
by F1 hybrid mice (OÈ hlen et al., 1989; and reviewed Antibodies
by Yokoyama, 1995; George et al., 1997). Although the MAbs and polyclonal antibodies specific for HLA class I or NK cell
alloreactivity of human NK cells is well known (Ciccone receptors were used for cell sorting, for flow cytometric analyses,
and as blocking reagents in cell-killing assays. The MAbs used wereet al. 1988, 1990a, 1990b, 1992; Colonna et al., 1992;
MAb DX17 (anti-HLA class I), MAb EB6 (anti-KIR2DL1 and anti-Bellone et al. 1993), its role in clinical bone marrow
KIR2DS1; Coulter, Hyalea, FL), MAb DX27 (anti-KIR2DL2/3 and anti-transplantation has not been worked out. The compari-
KIR2DS2), MAbDX9 (anti-KIR3DL1), MAb DX31 (anti-KIR3DL2), MAbson of PP and NV suggests that alloreactive NK cells
DX22 (anti-CD94), MAbLeu4 (anti-CD3; Becton Dickinson, Mountain
will, in almost all donor-recipient combinations, rely on View, CA),and MAb Leu19 (anti-CD56; Becton Dickinson). The spec-
KIR for their inhibitory receptors. Furthermore, the num- ificities of the DX9, DX17, DX22, DX27, and DX31 antibodies have
been described previously (SoÈ derstroÈ m et al., 1997). In flow cytome-ber of inhibitory KIR ligands provided by a person's
try experiments we also used a polyclonal rabbit antiserum specificHLA phenotype should correlate with the alloreactive
for the CD94:NKG2a heterodimer (Lazetic et al., 1996).potential of their NK cells: in general, a person's NK
cells will be alloreactive toward cells from individuals
Flow Cytometry
lacking the KIR ligands that he or she possesses and, Three-color flow cytometric analysis was performed on CD32CD561
conversely, will be tolerant of cells from individuals who PBMC and polyclonal cultured NK cells using the anti-receptor re-
have the same or additional KIR ligands. For inhibitory agents MAb EB6, MAb DX27, MAb DX9, MAb DX31, and an anti-
NKG2a rabbit polyclonal antiserum. Samples were analyzed usingKIR, the complexity of HLA class I polymorphism ap-
a FACScan flow cytometer (Becton Dickinson). The anti-CD3 andpears reduced to three ligands, which combine to
anti-CD56 reagents were conjugated with cychrome and fluoresceinproduce six different KIR±ligand phenotypes. In bone
isothiocyanate respectively, and the anti-KIR reagents were labeled
marrow transplantation these six phenotypes can be directly with phycoerythrin. The CD94:NKG2a±specific polyclonal
combined in 72 different ways. It is therefore feasible rabbit antiserum was detected using a phycoerythrin-conjugated
todetermine whether theprinciples governing the allore- goat anti-rabbit IgG (Caltag, Burlingame, CA). The percentage of
NK cells expressingeach class I receptor was calculated after gatingactions between PP and NV are generally applicable to
on the CD32CD561 lymphocyte subset.the population at large.
Generation of NK Cell Clones and Polyclonal
NK Cell CulturesExperimental Procedures
NK cell clones were generated and maintained as described (Yssel
et al., 1984; Litwin et al., 1993). In brief, PBMC were stained withCloning and Sequencing of HLA Class I and NK Cell
Receptor Transcripts antibodies for CD3 and CD56, and CD32CD561 NK cells were single-
cell sorted using a FACStar cell sorter and cyt-clone software andHLA class I cDNA clones were isolated from mRNA and sequenced
as described (Ennis et al., 1990; Domena et al., 1993). cDNA clones hardware (Becton Dickinson). The NK cell clones were cultured in
Iscove's modified Dulbecco's medium (Gibco±BRL, Gaithersburg,for each allele were subcloned into the PBJ1neo expression vector
(Lin etal., 1990) and transfected into 721.221cells (a class I±deficient MD) containing 200 U/ml recombinant interleukin-2 (kindly provided
by C. Reynolds, National Cancer Institute/Biological Response Mod-B lymphoblastoid cell line [BLCL]). Transfections and the selection,
maintenance, and characterization of the resulting transfectants ifiers Program, Frederick, MD). At the start of culture and weekly
thereafter the clones were cocultured with 1 3 106/ml irradiatedwere performed as described (Shimizu and DeMars, 1989; Litwin et
al., 1993). PBMC (allogeneic) and 1 3 105/ml Epstein-Barr virus (EBV)±
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transformed BLCL (JY). Cell-killing and PCR-typing assays were to form a natural killer cell inhibitory receptor for HLA class I mole-
cules. Eur. J. Immunol. 27, 563±567.performed 5±7 days after the addition of feeder cells. The PCR-
typing assays always contained cells from a ªfeeders onlyº culture, Chang, C., Rodriguez, A., Carretero, M., LoÂ pez-Botet, M., Phillips,
without NK cell clones, to control for false-positive signals that J.H., and Lanier, L.L. (1995). Molecular characterization of human
may result from amplification of residual KIR transcripts from the CD94: a type II membrane glycoprotein related to the C-type lectin
irradiated feeder cells. Polyclonal NK cells were cultured using do- superfamily. Eur. J. Immunol. 25, 2433±2437.
nor-derived PBMC and irradiated EBV-transformed stimulator cells Ciccone, E., Viale, O., Pende, D., Malnati, M., Biassoni, R., Melioli,
(RPMI-8866) as previously described (Perussia et al., 1987), without G., Moretta, A., Long, E.O., and Moretta, L. (1988). Specific lysis
modification. of allogeneic cells after activation of CD32 lymphocytes in mixed
lymphocyte culture. J. Exp. Med. 168, 2403±2408.
Cell-Killing Assays Ciccone, E., Colonna, M., Viale, O., Pende, D., Di Donato, C., Rein-
Cell-killing assays wereperformed using NK cell clones orpolyclonal harz, D., Amoroso, A., Jeannet, M., Guardiola, J., Spies, T., et al.
populations of NK cells as effectors and 51Cr-labeled target cells: PP- (1990a). Susceptibility or resistance to lysis by alloreactive natural
and NV-derived BLCL; 721.221 (untransfected); and 221-A*0101, killercells is governed by a gene in the human major histocompatibil-
-A*0201, -A*0301, -B*0702, -B*1501, -B*2702, -Cw*0202, -Cw*0304, ity complex between BF and HLA-B. Proc. Natl. Acad. Sci. USA 87,
and -Cw*0702 class I transfectants. Assays were done two or three 9794±9797.
times and in duplicate and were performed for 4 hr at an effector:tar-
Ciccone, E., Pende, D., Viale, O., Tambussi, G., Ferrini, S., Biassoni,
get ratio (E:T) of 6:1. In some assays anti-class I or anti-NK cell
R., Longo, A., Guardiola, J., Moretta, A., and Moretta, L. (1990b).
receptor antibodies were added (25 mg/ml), and these assays were
Specific recognition of human CD32CD161 natural killer cells re-
performed for 4 hr at an E:T of 10:1. The percentage specific lysis quires the expression of an autosomic recessive gene on target
was calculated with the following formula: (experimental release cells. J. Exp. Med. 172, 47±52.
[cpm] 2 spontaneous release [cpm]) / (maximum release [cpm] 2
Ciccone, E., Pende, D., Viale, O., Di Donato, C., Tripodi, G., Orengo,spontaneous release [cpm]) 3 100 5 percentage specific lysis.
A.M., Guardiola, J., Moretta, A., and Moretta, L. (1992). EvidenceSome results are presented as percentage inhibition compared to
of a natural killer (NK) cell repertoire for (allo) antigen recognition:lysis of untransfected 221 target cells, calculated using the following
definition of five distinct NK-determined allospecificities in humans.formula: 1 2 (% specific lysis of class I±deficient 221 targets / %
J. Exp. Med. 175, 709±718.specific lysis of class I1 targets) 3 100 5 percentage inhibition. All
Colonna, M., and Samaridis, J. (1995). Cloning of Ig-superfamilyclones lysed the untransfected 221 target cells at levels exceeding
members associated with HLA-C and HLA-B recognition by human50%, whereas lysis of the autologous B cell lines never exceeded
natural killer cells. Science 268, 405±408.10%.
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